Normalization of the serum-free light-chain ratio (FLCr) with the absence of bone marrow monoclonal plasma cells following achievement of a complete response (CR) to therapy denotes a stringent CR in multiple myeloma (MM), and is associated with improved overall survival (OS). However, its value in patients achieving o CR is not clear. We hypothesized that patients achieving a normalization of FLCr with initial therapy of MM will have an improved outcome, even in the absence of a CR. We retrospectively evaluated 449 patients with newly diagnosed MM with measurable disease at baseline, who did not achieve a CR with initial therapy. One hundred and fifty-three patients (34%) had a normal FLCr, whereas 296 (66%) had an abnormal ratio. Patients with a normal FLCr had a longer progression-free survival (29 vs 16 months, P o 0.001) and OS (91 vs 58 months, P o0.001). Normalization of FLCr retained its prognostic value in a multivariable model. Our results suggest an important role for sFLC measurement in disease monitoring even in patients who achieve only a partial response to therapy. Obtaining a normal FLCr confers a favorable prognosis independent from other factors, supporting the inclusion of sFLC in all levels of response criteria.
INTRODUCTION
Monoclonal gammopathies are characterized by secretion of monoclonal protein by the clonal plasma cells, which in the majority of patients is in the form of intact immunoglobulins. In addition to the intact monoclonal proteins, normal as well as clonal plasma cells also secrete kappa and lambda light chains unbound to a heavy chain.
1,2 These serum-free light chains can be quantitated by assays that utilize antibodies against epitopes on the free light chains that are typically hidden when bound to the heavy chain. In the vast majority of patients with monoclonal gammopathies, the clonal plasma cells secrete an excess of one of the light chains, thus disrupting the normal ratio between serumfree kappa and lambda light chains. [3] [4] [5] [6] In a smaller proportion of patients, clonal plasma cells only secrete free light chains and a clonal heavy chain cannot be identified. 7 The proportion of patients with elevated monoclonal free light chains increases with disease progression from monoclonal gammopathy of undetermined significance to smoldering myeloma to symptomatic multiple myeloma (MM). Baseline serum-free lightchain (sFLC) measurements have been shown to be of prognostic value in all types of monoclonal gammopathies, predicting progression in monoclonal gammopathy of undetermined significance and smoldering myeloma, and survival in MM. 3, 5, 8 More importantly, in MM, sFLC measurements allow assessment of response to therapy and have been integrated into the International Myeloma Working Group (IMWG) guidelines for response criteria. 3, 5, 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Although it is the primary marker of response among patients with light-chain myeloma and those without conventional levels of measurable disease by electrophoresis (o1 g/dl M-spike in serum protein electrophoresis or o200 mg/24 h in urine protein electrophoresis), it is also a key determinant of the depth of response in all patients with MM. The IMWG response criteria recently defined a new level of response, stringent complete response (CR), that requires a normalization of serum FLC ratio (FLCr) in addition to the conventional definition of CR with the absence of bone marrow clonal plasma cells. 19 Achievement of a stringent CR is associated with improved outcomes including overall survival (OS) and likely denotes a deeper tumor reduction.
Previous studies have explored the potential role of sFLC in the follow-up of non-light-chain MM and have produced different conclusions. Mori et al. 20 studied 73 patients who received an induction therapy with novel agents and suggested a prognostic value for the involved FLC (iFLC) level at the time of stem cell mobilization on survival outcomes. In a prior study, Dispenzieri et al. 8 found no utility for adding sFLC measurement 2 months after therapy with alkylating agents in MM with measurable disease. In a recent Japanese study, Iwama et al. 21 studied the effect of normalization of FLCr after treatment in 126 newly diagnosed MM patients and showed that normal FLCr was associated with longer OS, regardless of other factors. However, these studies have not examined the role of FLC measurements in the group of patients with residual intact immunoglobulin monoclonal protein (less than CR) at the time of maximal response following therapy. We designed this study to specifically examine the value of the FLC measurements in a cohort of patients with non-light-chain MM, who have residual monoclonal protein on serum protein electrophoresis following initial therapy of myeloma (patients with less than a CR).
PATIENTS AND METHODS Patients
We initially identified 1346 patients with newly diagnosed MM patients seen at the Mayo Clinic in Rochester, MN between January 2004 and December 2011. The dates were selected based on the date of serum FLC assay becoming routinely available in the clinical laboratory. We then selected patients with measurable disease on serum protein electrophoresis, defined as a serum M-spike ⩾ 1 g/dl at the time of diagnosis. Finally, we excluded all patients with negative immunofixation for monoclonal M-protein in serum and urine, patients who did not have serum FLC results available from the time of their first best response or had biclonal disease with kappa and lambda FLCs. After applying the inclusion and exclusion criteria, a total of 449 patients were included in our study (Supplementary Figure 1) . The Mayo Clinic Institutional Review Board, in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act guidelines of 1996, approved the study. An informed consent was obtained from all patients included in the study.
Data were obtained from existing databases and review of medical records. We collected the serum electrophoresis results and sFLC values that corresponded with the date of the best response following diagnosis. M-protein measurements were collected serially until the time of the first relapse or last follow-up date if no relapse was recorded. The FLC assay (FREELITE, The Binding Site, Birmingham, UK) was performed as part of routine clinical care as previously described. We used the following ranges as our reference for normal FLC values; κ FLC (0.33-1.94 mg/dl), λ FLC (0.57-2.63 mg/dl), and (0.26-1.65) for the sFLC κ/λ ratio (FLCr). dFLC was defined as the absolute difference between the kappa and lambda FLC levels.
Statistical analysis
We examined the impact of both FLCr normalization and normalization of the involved sFLC (iFLC) at the time of best response, as well as the value of baseline FLC levels. For the purpose of analyzing baseline FLC, we dichotomized patients into high dFLC (⩾10 mg/dl) (n = 234) and low dFLC (o10 mg/dl) (n = 126). Eighty-nine patients did not have a serum FLC assay available at the time of diagnosis.
Statistical analysis was done using JMP 10 software package (SAS Institute Inc., Cary, NC, USA). Progression-free survival (PFS) and OS were analyzed using the Kaplan-Meier method and compared using the logrank test. Multivariate analysis was performed using the Cox proportional hazards model to assess the influence of a number of variables on PFS and OS.
RESULTS

Patient characteristics
The baseline demographics and disease characteristics of all 449 patients are shown in Table 1 . The median age of the cohort at the time of diagnosis was 65 years (range, 29-91); 13% were older than 75 years and 281 (63%) were male. The estimated median follow-up for the whole cohort was 5.5 years (95% confidence interval (CI): 5.0, 5.9); 240 (53%) patients were alive with a median follow-up of 4.7 years (range, 0.4-10). Three hundred and seventy (82%) patients had relapsed following the initial therapy with a median time to progression of 19.5 months (95% CI: 18, 22). The median PFS for the entire cohort was 18.8 months (95% CI: 17, 21) and the OS was 67 months (95% CI: 60, 73), both from diagnosis. Baseline FLC measurements were available in 360 (80%) patients; 339 (94%) of them had an abnormal FLCr and a dFLC of ⩾ 10 mg/dl was seen in 234 (65%) patients.
Treatment and response
The most common first-line therapy was lenalidomide with or without dexamethasone in 212 (47%) patients and additional 34 (8%) patients received cyclophosphamide or melphalan in combination with lenalidomide and dexamethasone. A bortezomibbased regimen was used in 60 (13%) patients and additional 15 (3%) and 4 (1%) patients received bortezomib-lenalidomidedexamethasone and bortezomib-thalidomide-dexamethasone, respectively. A total of 45 (10%) patients received a thalidomidebased regimen and the remaining 79 (18%) patients received conventional therapies. A partial response (PR) or better was seen among 363 (81%) of patients including 144 (32%) with a very good partial remission and 219 (49%) with a PR. The median time to the best first response for the whole cohort was 6.9 months (range: 0.3-83 months). The PFS from diagnosis was 21 months (95% CI: 19, 24) for those achieving a PR or better compared with 7 months (95% CI: 5, 12) for the remainder; Po 0.001 (Supplementary Figure 2A) . The differences were significant even with the analysis performed after landmarking at 1 year from diagnosis, thus allowing patients adequate time to respond to therapy (Supplementary Figure 2B) . The OS from diagnosis was 73 months (95% CI: 64, 99) for those achieving a PR or better compared with 49 months (95% CI: 32, 58) for the remainder, Po 0.001 (Supplementary Figure 2C) and was similar when landmarked at 1 year from diagnosis (Supplementary Figure 2D) . sFLC response to treatment and outcome Normalization of FLCr at the time of the best first response was seen in 153 (34%) patients and normalization of iFLC level was seen in 199 (44%) patients. Only 122 patients (27%) achieved both normal iFLC level and FLCr. The median time to the best first response was 10 months (range: 0.7-83 months) in patients who achieved a normal sFLCr and 6 months (range: 0.3-48 months) for patients who did not achieve a normal sFLCr. The proportion of patients with FLCr or iFLC normalization within each IMWG response category is shown in Figure 1 . Patients who achieved a normal FLCr had a longer PFS compared with those who did not Figure 2a ) and also had a longer OS (91 vs 58 months, P o 0.001; Figure 2b) . Patients who achieved a normal iFLC level as compared with those who did not had a longer PFS (23 vs 15 months, P o 0.001; Figure 2c ) and OS (73 vs 58 months, P o 0.001; Figure 2d ).
We then looked at the difference in survival outcomes after grouping patients who achieved a normal iFLC (n = 199) into two groups: those who achieved normal FLCr and those who did not. Among the patients achieving a normal iFLC level, those who achieved a normal FLCr had a longer PFS (30 vs 20 months, P o0.002) and OS (99 vs 65 months, P = 0.02) compared with those who did not. However, we saw no significant differences in PFS or OS when grouping patients who achieved a normal sFLC κ/λ ratio into those who achieved a normal iFLC level and those who did not.
We specifically compared survival outcomes of patients who achieved a normal FLCr with those who did not achieve a normal FLCr, within each of the IMWG response categories (Table 2) . We found that FLCr normalization had a favorable impact on PFS in each of the three groups (very good partial response, PR and stable disease+progressive disease). However, when looking at the OS, only patients with PR had a better OS associated with a normal sFLC κ/λ ratio.
Finally, in univariable analysis, conventional prognostic factors, such as age 465 years, serum creatinine 42 mg/dl, International Staging System stage 3 at diagnosis, lactate dehydrogenase 4222 as well as normalization of FLCr were all prognostic for OS. In a multivariate model that included all these variables (253 patients with all variables available), normalization of FLCr, International (a) Progression-free survival: comparing patients who achieved normal sFLC κ/λ ratio at the time of the best first response with patients who did not achieve normal sFLC κ/λ ratio. (b) Overall survival: comparing patients who achieved normal sFLC κ/λ ratio at the time of the best first response with patients who did not achieve normal sFLC κ/λ ratio. (c) Progression-free survival: comparing patients who achieved normal involved FLC level at the time of the best first response with patients who did not achieve normal involved FLC level. (d) Overall survival: comparing patients who achieved normal involved FLC level at the time of the best first response with patients who did not achieve normal involved FLC level. NR, not reached.
Staging System stage 3 and lactate dehydrogenase 4222 were all prognostic for OS. When iFLC normalization was substituted for FLCr normalization in the same multivariable model, only lactate dehydrogenase and International Staging System were significant. Only a minority of patients had fluorescent in situ hybridization data from diagnosis and hence this was not included in the analysis.
We also attempted to examine the impact of the treatment type on our findings. Among patients receiving lenalidomide-containing therapy and those receiving conventional therapies, the impact of FLCr normalization was significant, similar to the overall population. However, in patients receiving bortezomib-or thalidomidecontaining regimens, the findings were not significant, but the small number of patients in these groups limits these comparisons. 
Serum-free light chain ratio in partial response
Prognostic impact of sFLC measurements in relation to baseline FLC measurements The baseline free light-chain measurements were available in 360 (80%) of the total cohort. Out of the 360 patients, only 21 (6%) had a normal baseline FLCr, those patients had better OS as compared with the 339 (94%) who had abnormal ratio (median not reached vs 65 months, P = 0.03). One hundred and twenty-six (36%) patients had a dFLC of o 10 mg/dl at baseline, those patients had a superior OS compared with the remainder of the patients; median not reached vs 61 months, P = 0.02 (Figure 3a) . We specifically examined the impact of normalization of FLCr among patients with low or high levels of dFLC at baseline on the PFS and OS. In both groups with low and high levels of dFLC, patients who achieved normal FLCr had a better PFS (Figures 3b and c,  respectively) . However, achievement of normal FLCr improved OS in patients with high baseline dFLC ⩾ 10 ( Figure 3d ) and not in patients with low baseline dFLC. We also examined the specific baseline clinical and laboratory factors associated with normalization of the FLCr (Table 3 ). Lower measures of baseline FLC levels were associated with a higher probability of normalization, as might be expected.
DISCUSSION
The sFLC assay provides valuable information in all stages of the disease including precursor states such as monoclonal gammopathy of undetermined significance, smoldering myeloma and plasmacytomas, where it remains an excellent marker of future progression risk. 3, 5, 9 It is the primary marker of hematological response in light-chain amyloidosis. 22 It has also been shown to be prognostic in patients with newly diagnosed myeloma, and remains an integral part of the current response criteria with stringent CR defined partly on this assessment. In the current study, we have been able to demonstrate utility for serum FLC measurements in patients who still have a measurable intact immunoglobulin M-spike. In addition, the findings raise important questions regarding the biology of free light-chain excretion by plasma cells in relation to intact immunoglobulin. We recognized the prognostic impact of sFLC κ/λ ratio normalization in patients with residual intact monoclonal immunoglobulin in the serum, and we show an improved PFS for patients who achieved a normal ratio after the initial therapy, regardless of their IMWG response level. This prognostic value was more significant in patients with PR and was translated into substantially better OS in this group (Table 2) .
The role of serum FLC measurements was proposed in an earlier preliminary study (Mead et al. 23 ), which suggested a possible role of serum FLC measurement in patients with measurable disease. This mainly was based on the fact that FLCs have short half-lives compared with the intact immunoglobulins, and thus could provide a more rapid indicator of tumor reduction in response to therapy; however, this study did not look at the effect of attaining normal serum FLC levels on survival outcomes. More recently, Iwama et al. 21 showed that achieving a normal sFLCr correlated with improved PFS and OS in patients who had a PR or very good partial remission as their maximal response, but this study did not look at the patients with intact immunoglobulins separately and the analysis was done on all MM patients.
On the other hand, one large study failed to confirm any prognostic value of follow-up measurements of FLC on survival outcomes in newly diagnosed myeloma patients with measurable disease, when added to the M-protein measurements. However, this study cannot be compared methodologically with our study, as the FLC measurements were done at a fixed time point of 2 months after initiating therapy and the FLC response was measured as a 50% reduction in dFLC, iFLC or FLCr, with the study focus on the early changes in FLC. In addition, the therapy used in the mentioned study did not include novel agents. 8 In contrast, the current study used the complete normalization of the FLCr as the FLC response criteria at the time of the maximal response (median for the best first response was 6.9 months). However, it should be noted that our study is limited by its retrospective nature and the lack of predefined schedules for response assessments. Our study is also based on patients seen at a referral center, and about 20% of the patients did not have baseline sFLC measurements. Other limitations to our study are the variety of the anti-myeloma therapies used as well as variable duration of the treatments. We have tried to limit the heterogeneity by examining the first response obtained after diagnosis in these patients. Despite these limitations, our study is the largest to date Abbreviations: CI, confidence interval; dFLC, absolute difference between the kappa and lambda FLC levels; FLCr, free light-chain ratio; iFLC, involved free light chain; OR, odds ratio; PR, partial response.
looking at the benefit of FLC in monitoring MM patients with intact immunoglobulin, and our results largely confirm the beneficial role of serial sFLC measurements in this group of patients.
In conclusion, it appears that obtaining a normal sFLC ratio confers a more favorable prognosis irrespective of the depth of the response, which may represent an effective eradication of a plasma cell subclone that secretes these free light chains. This would be consistent with the prior findings of inferior outcomes seen among patients with myeloma with higher levels of serum FLC at presentation. We suggest an important role for sFLC measurements in disease monitoring even in patients who achieve only a PR to therapy. Conceivably, this can be done at the time the patient achieves their maximal response to a given therapy (instead of serial measurements at every time point), and future studies should be designed to examine whether alterations in therapy based on these results will alter long-term outcomes. These results support the inclusion of sFLC at all levels of response included in the current IMWG criteria.
